Mei Pharma’s foray into the world of cryptocurrency has rocked the biotech and crypto spaces. Known as Mei Pharma’s Litecoin treasury, the San Diego based company broke into the news with a bold step, they put $110.4 million into Litecoin (LTC) which they have made to be the main element of their treasury reserve. This is a first in the U.S. for a public company which is seeing Mei Pharma put its money behind the digital currency.
Between the 30th of July and the 4th of August Mei Pharma bought 929,548 LTC tokens at an average price of $107.58. They funded this with a $100 million private placement which saw them sell 29 million shares at $3.42 each. This move not only represents a change in investment focus but also puts out a signal of great trust in Litecoin’s long term value.
Mei Pharma’s Litecoin Treasury Is Joined By Charlie Lee And GSR
To push this game changing strategy forward Mei Pharma brought in Charlie Lee the founder of Litecoin to the board. His return to a front line role adds weight to the initiative. Lee reports that the company is into sound scalable digital money which has Litecoin at the core of its institution finance.
Mei Pharma also partnered with GSR, the leading crypto market player. GSR in this case is a treasury advisor and digital asset manager. They provide liquidity support, execution and put forth governance structures which are meant for institutional adoption. GSR’s Chief Strategy Officer, Josh Riezman, reported that this is a “breakthrough institution scale play we’ve designed with Litecoin.
Mei Pharma’s Crypto Fund Sets Off A Market Surge.
Following that report, Litecoin saw a 10.9% rise which at one point hit $128.30. For the week it was the best performing asset in the top 100. The equity market saw Mei Pharma’s share price jump to $5.30 which is an 87% increase over the last 6 months. This great performance is an indicator of growing institution interest in crypto diversity.
Analyst reports that the chance of a Litecoin ETF going through in 2025 is high. Also with clear regulatory classification as a commodity and what it takes in terms of stable operation, Litecoin is put into play for mainstream finance.
Mei Pharma’s Crypto Investment Drives Corporate Rebirth.
This is a piece of the Mei Pharma’s larger transformation. They also plan to change their brand and may get into Litecoin mining, crypto currency mining and also fintech. But they will not leave their pharmaceutical mission which includes research of cancer drug voruciclib and other therapies out. Also this research will run parallel to the new ventures.
2024 saw a shift which is centered around Litecoin. This came out of a strategic review that went through to do what could to maximize shareholder value. Instead of selling off assets Mea Pharma chose to use blockchain finance for innovation. Combining long term asset growth with improved operational resilience.
As the out of the gate player in this field Mei Pharma has set a trend. If successful, other companies may follow, in particular those looking for what we do instead of Bitcoin for their treasury diversification.
